



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

April 2015





# HIV/AIDS Drug Treatment Program

## Monthly Report

© 2015 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.682.8202  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)



BRITISH COLUMBIA  
CENTRE for EXCELLENCE  
in HIV/AIDS



This document is best viewed in colour.  
Drug definitions available in the back.



## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





## TABLE OF CONTENTS

### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

April 2015

N = 6856



Health Authority	Male	Female	All
FRASER	1263	383	1646
INTERIOR	336	93	429
NORTHERN	133	79	212
VANCOUVER COASTAL	3336	442	3778
VANCOUVER ISLAND	621	145	766
	<b>5689</b>	<b>1142</b>	<b>6831</b>
		<b>Unknown/not stated:</b>	<b>25</b>
		<b>Total:</b>	<b>6856</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (April 2010 - April 2015)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (April 2010 - April 2015)








### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (April 2010 - April 2015)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (April 2010 - April 2015)






1.6 Percent Distribution of Active Participants by CD4 Count (April 2010 - April 2015)






1.7 Percent Distribution of Inactive Participants by CD4 Count (April 2010 - April 2015)






### 1.8 Active and Inactive Participants (April 2010 - April 2015)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (April 2010 - April 2015)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (April 2010 - April 2015)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(April 2010 - April 2015)








1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT  
(April 2010 - April 2015)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(April 2010 - April 2015)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (April 2010 - April 2015)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(April 2010 - April 2015)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (April 2010 - April 2015)






### 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(April 2010 - April 2015)






1.18 Baseline CD4 for Antiretroviral First Starts (April 2010 - April 2015)






### 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (April 2010 - April 2015)








### 1.20 Cumulative Resistance Testing Results by Resistance Category (April 2010 - April 2015)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (April 2010 - April 2015)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2015  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	23	5	0	5	5	800	5	<40	4
1988	23	7	0	7	7	490	7	<40	4
1989	22	55	2	57	53	510	57	<40	4
1990	21	63	1	64	59	530	63	<40	4
1991	21	39	3	42	35	590	41	<40	4
1992	21	68	7	75	59	570	75	<40	4
1993	20	143	14	157	143	570	154	<40	4
1994	19	95	13	108	90	540	105	<40	4
1995	18	123	27	150	127	580	146	<40	4
1996	16	384	63	447	373	580	429	<40	4
1997	14	318	40	358	321	580	351	<40	3
1998	14	225	43	268	222	555	254	<40	3
1999	14	187	43	230	193	560	221	<40	3
2000	14	143	40	183	152	590	174	<40	3
2001	13	136	38	174	142	525	168	<40	3
2002	12	141	31	172	142	540	163	<40	3
2003	12	176	35	211	184	575	202	<40	3
2004	11	182	45	227	189	560	212	<40	3
2005	10	214	52	266	223	620	254	<40	4
2006	9	223	52	275	224	536	260	<40	4
2007	8	283	58	341	282	580	326	<40	3
2008	7	329	76	405	335	630	389	<40	3
2009	6	354	76	430	365	620	415	<40	3
2010	5	323	77	400	332	620	381	<40	3
2011	4	381	80	461	397	620	444	<40	3
2012	3	322	69	391	334	650	376	<40	3
2013	2	303	73	376	302	606	358	<40	3
2014	1	335	61	396	346	620	389	<40	3
2015	0	133	23	156	147	520	151	120	4
<b>Total:</b>		<b>5690</b>	<b>1142</b>	<b>6832</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	6557	784	2429	<40	2151	560
FEB-2014	6570	784	1895	<40	1656	550
MAR-2014	6598	788	2156	<40	1927	550
APR-2014	6611	790	2126	<40	1873	560
MAY-2014	6677	769	2119	<40	1887	560
JUN-2014	6644	784	1994	<40	1768	550
JUL-2014	6682	780	2179	<40	1930	550
AUG-2014	6703	775	2026	<40	1803	570
SEP-2014	6730	770	2284	<40	2003	550
OCT-2014	6760	764	2250	<40	1956	570
NOV-2014	6758	761	1920	<40	1703	580
DEC-2014	6772	766	1895	<40	1682	580
JAN-2015	6746	762	2428	<40	2103	580
FEB-2015	6801	753	1980	<40	1700	570
MAR-2015	6848	748	2175	<40	1832	570
APR-2015	6856	739	2145	<40	1805	590

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2014	1418	2266	100	6683	76	285
FEB-2014	1439	2213	73	496	67	490
MAR-2014	1441	2179	115	3890	98	340
APR-2014	1451	2159	112	128	90	400
MAY-2014	1422	2331	90	617	76	350
JUN-2014	1475	2074	96	423	82	380
JUL-2014	1467	2119	95	982	76	355
AUG-2014	1459	2183	87	208	72	365
SEP-2014	1459	2191	104	949	90	395
OCT-2014	1447	2273	84	257	62	395
NOV-2014	1460	2244	74	3945	64	400
DEC-2014	1479	2218	93	557	72	340
JAN-2015	1517	2083	105	1364	83	300
FEB-2015	1495	2183	98	74	82	380
MAR-2015	1468	2321	101	75	85	400
APR-2015	1477	2290	82	2279	63	500

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2014	6539	1418	2	30	144	136	35	11501
FEB-2014	6548	1439	9	40	139	159	9	11545
MAR-2014	6573	1441	9	36	151	146	25	11589
APR-2014	6587	1451	5	27	159	161	14	11625
MAY-2014	6646	1422	14	38	191	152	59	11675
JUN-2014	6618	1475	7	24	142	183	-28	11713
JUL-2014	6659	1467	8	34	176	159	41	11757
AUG-2014	6683	1459	6	18	165	149	24	11789
SEP-2014	6713	1459	2	25	168	159	30	11828
OCT-2014	6738	1447	7	21	159	146	25	11855
NOV-2014	6732	1460	12	19	135	144	-6	11879
DEC-2014	6747	1479	7	39	136	147	15	11928
JAN-2015	6714	1517	13	24	147	185	-33	11963
FEB-2015	6773	1495	7	37	190	160	59	12016
MAR-2015	6827	1468	7	30	173	141	54	12057
APR-2015	6832	1477	12	27	169	176	5	12092

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2014	47	6025	414	71	<b>6557</b>	0.72%	91.89%	6.31%	1.08%	<b>100.00%</b>
FEB-2014	50	6034	418	68	<b>6570</b>	0.76%	91.84%	6.36%	1.04%	<b>100.00%</b>
MAR-2014	50	6054	424	70	<b>6598</b>	0.76%	91.76%	6.43%	1.06%	<b>100.00%</b>
APR-2014	46	6067	422	76	<b>6611</b>	0.70%	91.77%	6.38%	1.15%	<b>100.00%</b>
MAY-2014	47	6138	418	74	<b>6677</b>	0.70%	91.93%	6.26%	1.11%	<b>100.00%</b>
JUN-2014	49	6108	416	71	<b>6644</b>	0.74%	91.93%	6.26%	1.07%	<b>100.00%</b>
JUL-2014	46	6148	415	73	<b>6682</b>	0.69%	92.01%	6.21%	1.09%	<b>100.00%</b>
AUG-2014	46	6171	414	72	<b>6703</b>	0.69%	92.06%	6.18%	1.07%	<b>100.00%</b>
SEP-2014	50	6185	424	71	<b>6730</b>	0.74%	91.90%	6.30%	1.05%	<b>100.00%</b>
OCT-2014	44	6209	434	73	<b>6760</b>	0.65%	91.85%	6.42%	1.08%	<b>100.00%</b>
NOV-2014	47	6217	424	70	<b>6758</b>	0.70%	91.99%	6.27%	1.04%	<b>100.00%</b>
DEC-2014	45	6232	421	74	<b>6772</b>	0.66%	92.03%	6.22%	1.09%	<b>100.00%</b>
JAN-2015	46	6186	440	74	<b>6746</b>	0.68%	91.70%	6.52%	1.10%	<b>100.00%</b>
FEB-2015	42	6234	452	73	<b>6801</b>	0.62%	91.66%	6.65%	1.07%	<b>100.00%</b>
MAR-2015	43	6302	436	67	<b>6848</b>	0.63%	92.03%	6.37%	0.98%	<b>100.00%</b>
APR-2015	42	6313	435	66	<b>6856</b>	0.61%	92.08%	6.34%	0.96%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	Lamivudine		Abacavir		Zidovudine		Stavudine		Didanosine		Emtricitabine		Tenofovir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	8 19%	2381 37%	7 17%	1994 31%	0 0%	144 2%	0 0%	25 0%	0 0%	17 0%	33 79%	3863 61%	36 86%	4270 67%
FEB-2014	7 16%	2383 37%	7 16%	1992 31%	0 0%	140 2%	0 0%	25 0%	0 0%	16 0%	37 84%	3880 61%	37 84%	4286 67%
MAR-2014	7 16%	2386 37%	6 14%	2007 31%	0 0%	140 2%	0 0%	22 0%	0 0%	13 0%	37 84%	3893 61%	38 86%	4298 67%
APR-2014	3 8%	2396 37%	3 8%	2022 32%	0 0%	137 2%	0 0%	22 0%	0 0%	12 0%	33 92%	3904 61%	33 92%	4301 67%
MAY-2014	17 34%	2434 38%	16 32%	2058 32%	1 2%	137 2%	0 0%	21 0%	0 0%	13 0%	33 66%	3929 61%	33 66%	4325 67%
JUN-2014	8 21%	2431 38%	9 24%	2063 32%	0 0%	130 2%	0 0%	20 0%	1 3%	13 0%	29 76%	3905 61%	29 76%	4293 67%
JUL-2014	13 30%	2462 38%	11 25%	2095 32%	1 2%	129 2%	0 0%	22 0%	0 0%	13 0%	31 70%	3918 60%	32 73%	4298 66%
AUG-2014	7 23%	2474 38%	7 23%	2108 32%	0 0%	132 2%	0 0%	21 0%	0 0%	11 0%	24 77%	3913 60%	24 77%	4287 66%
SEP-2014	15 38%	2517 39%	12 31%	2146 33%	3 8%	136 2%	0 0%	18 0%	0 0%	12 0%	24 62%	3905 60%	24 62%	4285 66%
OCT-2014	10 37%	2546 39%	9 33%	2173 33%	0 0%	134 2%	0 0%	18 0%	0 0%	12 0%	17 63%	3906 60%	17 63%	4287 65%
NOV-2014	6 25%	2548 39%	6 25%	2183 33%	0 0%	129 2%	0 0%	18 0%	0 0%	12 0%	17 71%	3896 59%	19 79%	4269 65%
DEC-2014	13 27%	2576 39%	9 18%	2205 34%	3 6%	129 2%	0 0%	19 0%	0 0%	11 0%	36 73%	3876 59%	37 76%	4248 65%
JAN-2015	10 29%	2585 40%	10 29%	2222 34%	0 0%	127 2%	0 0%	19 0%	0 0%	11 0%	25 71%	3851 59%	25 71%	4215 64%
FEB-2015	9 17%	2595 39%	9 17%	2230 34%	0 0%	127 2%	0 0%	19 0%	0 0%	9 0%	44 83%	3893 59%	44 83%	4256 64%
MAR-2015	11 27%	2614 39%	11 27%	2257 34%	0 0%	124 2%	0 0%	18 0%	0 0%	10 0%	30 73%	3925 59%	30 73%	4281 64%
APR-2015	11 32%	2629 40%	11 32%	2271 34%	0 0%	117 2%	0 0%	16 0%	0 0%	9 0%	22 65%	3920 59%	22 65%	4276 64%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS







**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	(fos)amprenavir		Atazanavir		Darunavir		Lopinavir		Nelfinavir		Ritonavir		Saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	0 0%	19 1%	10 59%	2306 65%	7 41%	738 21%	0 0%	471 13%	0 0%	6 0%	0 0%	3 0%	0 0%	28 1%
FEB-2014	0 0%	19 1%	12 57%	2287 64%	7 33%	761 21%	2 10%	470 13%	0 0%	4 0%	0 0%	2 0%	0 0%	27 1%
MAR-2014	0 0%	18 1%	8 47%	2266 64%	7 41%	788 22%	2 12%	475 13%	0 0%	5 0%	0 0%	2 0%	0 0%	26 1%
APR-2014	0 0%	18 1%	11 52%	2259 63%	10 48%	811 23%	0 0%	468 13%	0 0%	3 0%	0 0%	2 0%	0 0%	26 1%
MAY-2014	0 0%	16 0%	7 41%	2249 64%	9 53%	815 23%	1 6%	456 13%	0 0%	4 0%	0 0%	3 0%	0 0%	25 1%
JUN-2014	0 0%	16 0%	5 31%	2198 63%	9 56%	831 24%	2 13%	449 13%	0 0%	5 0%	0 0%	3 0%	0 0%	25 1%
JUL-2014	0 0%	15 0%	10 59%	2182 63%	6 35%	851 24%	1 6%	433 12%	0 0%	5 0%	0 0%	1 0%	0 0%	26 1%
AUG-2014	0 0%	14 0%	2 20%	2153 62%	8 80%	856 25%	0 0%	425 12%	0 0%	5 0%	0 0%	1 0%	0 0%	24 1%
SEP-2014	0 0%	14 0%	4 31%	2139 62%	6 46%	868 25%	3 23%	424 12%	0 0%	5 0%	0 0%	1 0%	0 0%	21 1%
OCT-2014	0 0%	14 0%	3 30%	2133 62%	5 50%	889 26%	2 20%	407 12%	0 0%	4 0%	0 0%	1 0%	0 0%	19 1%
NOV-2014	0 0%	15 0%	10 83%	2107 62%	2 17%	893 26%	0 0%	397 12%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
DEC-2014	0 0%	13 0%	7 32%	2075 61%	12 55%	922 27%	3 14%	385 11%	0 0%	5 0%	0 0%	1 0%	0 0%	19 1%
JAN-2015	0 0%	12 0%	6 50%	2030 60%	6 50%	933 28%	0 0%	383 11%	0 0%	4 0%	0 0%	1 0%	0 0%	18 1%
FEB-2015	0 0%	10 0%	8 31%	2032 60%	18 69%	963 28%	0 0%	380 11%	0 0%	5 0%	0 0%	1 0%	0 0%	17 1%
MAR-2015	0 0%	11 0%	8 47%	2048 60%	8 47%	974 29%	0 0%	375 11%	1 6%	6 0%	0 0%	1 0%	0 0%	17 0%
APR-2015	0 0%	12 0%	6 30%	2028 60%	14 70%	991 29%	0 0%	364 11%	0 0%	6 0%	0 0%	1 0%	0 0%	18 1%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	Tipranavir			
	Initial		All	
JAN-2014	0	0%	1	0%
FEB-2014	0	0%	0	0%
MAR-2014	0	0%	1	0%
APR-2014	0	0%	1	0%
MAY-2014	0	0%	1	0%
JUN-2014	0	0%	1	0%
JUL-2014	0	0%	1	0%
AUG-2014	0	0%	1	0%
SEP-2014	0	0%	1	0%
OCT-2014	0	0%	1	0%
NOV-2014	0	0%	1	0%
DEC-2014	0	0%	1	0%
JAN-2015	0	0%	1	0%
FEB-2015	0	0%	1	0%
MAR-2015	0	0%	1	0%
APR-2015	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	Efavirenz		Etravirine		Nevirapine		Ralpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	12 80%	1342 48%	1 7%	304 11%	0 0%	948 34%	2 13%	233 8%
FEB-2014	12 71%	1343 48%	0 0%	305 11%	0 0%	942 33%	5 29%	244 9%
MAR-2014	10 71%	1320 47%	0 0%	298 11%	0 0%	943 34%	4 29%	253 9%
APR-2014	4 57%	1304 47%	0 0%	302 11%	1 14%	941 34%	2 29%	260 9%
MAY-2014	5 71%	1298 46%	0 0%	299 11%	0 0%	938 34%	2 29%	263 9%
JUN-2014	4 50%	1280 46%	1 13%	303 11%	1 13%	926 34%	2 25%	258 9%
JUL-2014	8 73%	1261 46%	0 0%	304 11%	1 9%	927 34%	2 18%	257 9%
AUG-2014	11 85%	1260 46%	1 8%	304 11%	0 0%	928 34%	1 8%	254 9%
SEP-2014	8 73%	1254 46%	0 0%	300 11%	2 18%	928 34%	1 9%	251 9%
OCT-2014	3 60%	1231 45%	2 40%	306 11%	0 0%	921 34%	0 0%	255 9%
NOV-2014	2 100%	1207 45%	0 0%	302 11%	0 0%	911 34%	0 0%	252 9%
DEC-2014	8 62%	1191 45%	0 0%	304 11%	1 8%	901 34%	4 31%	254 10%
JAN-2015	6 75%	1174 45%	0 0%	306 12%	0 0%	901 34%	2 25%	254 10%
FEB-2015	4 50%	1170 45%	0 0%	306 12%	0 0%	893 34%	4 50%	251 10%
MAR-2015	7 88%	1167 45%	0 0%	303 12%	0 0%	890 34%	1 13%	255 10%
APR-2015	4 67%	1147 44%	1 17%	305 12%	0 0%	888 34%	1 17%	259 10%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	Dolutegravir		Elvitegravir		Maraviroc		Raltegravir		Enfuvirtide	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2014	4 31%	13 1%	6 46%	154 13%	0 0%	79 7%	3 23%	926 81%	0 0%	2 0%
FEB-2014	1 17%	19 2%	5 83%	163 14%	0 0%	77 7%	0 0%	939 81%	0 0%	2 0%
MAR-2014	1 8%	31 3%	8 62%	179 15%	0 0%	78 6%	4 31%	947 79%	0 0%	2 0%
APR-2014	4 50%	78 6%	2 25%	198 16%	0 0%	82 7%	2 25%	953 76%	0 0%	2 0%
MAY-2014	16 64%	138 10%	6 24%	220 16%	0 0%	80 6%	3 12%	948 71%	0 0%	1 0%
JUN-2014	7 47%	187 13%	7 47%	237 17%	0 0%	77 6%	1 7%	930 67%	0 0%	2 0%
JUL-2014	10 59%	247 17%	5 29%	253 17%	0 0%	75 5%	2 12%	932 64%	0 0%	2 0%
AUG-2014	6 55%	298 20%	3 27%	268 18%	0 0%	75 5%	2 18%	919 61%	0 0%	2 0%
SEP-2014	7 47%	355 22%	4 27%	281 18%	0 0%	73 5%	4 27%	919 58%	0 0%	1 0%
OCT-2014	7 47%	406 25%	6 40%	309 19%	0 0%	71 4%	2 13%	906 55%	0 0%	1 0%
NOV-2014	5 45%	452 27%	5 45%	325 19%	0 0%	70 4%	1 9%	893 53%	0 0%	1 0%
DEC-2014	11 65%	500 29%	6 35%	336 19%	0 0%	72 4%	0 0%	888 51%	0 0%	1 0%
JAN-2015	13 72%	541 30%	4 22%	350 19%	1 6%	68 4%	1 6%	879 49%	0 0%	1 0%
FEB-2015	15 60%	578 31%	8 32%	358 19%	0 0%	74 4%	2 8%	882 48%	0 0%	1 0%
MAR-2015	10 53%	603 32%	5 26%	369 20%	0 0%	69 4%	4 21%	870 47%	0 0%	2 0%
APR-2015	7 50%	633 33%	4 29%	374 20%	2 14%	67 4%	1 7%	862 45%	0 0%	2 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2014	2572	39.23	2316	35.32	551	8.40	191	2.91	71	1.08	856	13.05
FEB-2014	2555	38.89	2319	35.30	579	8.81	189	2.88	68	1.04	860	13.09
MAR-2014	2560	38.80	2310	35.01	606	9.18	188	2.85	70	1.06	864	13.09
APR-2014	2542	38.45	2288	34.61	653	9.88	192	2.90	76	1.15	860	13.01
MAY-2014	2537	38.00	2275	34.07	739	11.07	193	2.89	74	1.11	859	12.87
JUN-2014	2502	37.66	2246	33.80	782	11.77	183	2.75	71	1.07	860	12.94
JUL-2014	2493	37.31	2235	33.45	840	12.57	191	2.86	73	1.09	850	12.72
AUG-2014	2465	36.77	2232	33.30	890	13.28	186	2.77	72	1.07	858	12.80
SEP-2014	2437	36.21	2221	33.00	946	14.06	187	2.78	71	1.05	868	12.90
OCT-2014	2420	35.80	2190	32.40	1008	14.91	192	2.84	73	1.08	877	12.97
NOV-2014	2422	35.84	2159	31.95	1056	15.63	184	2.72	70	1.04	867	12.83
DEC-2014	2398	35.41	2146	31.69	1104	16.30	185	2.73	74	1.09	865	12.77
JAN-2015	2350	34.84	2125	31.50	1138	16.87	179	2.65	74	1.10	880	13.04
FEB-2015	2370	34.85	2113	31.07	1181	17.37	178	2.62	73	1.07	886	13.03
MAR-2015	2406	35.13	2113	30.86	1208	17.64	185	2.70	67	0.98	869	12.69
APR-2015	2398	34.98	2094	30.54	1245	18.16	184	2.68	66	0.96	869	12.68

**Definitions:**

n is number of participants on the specified regimen class in the specified month  
 % is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2014	30	6	2	9	4	9	300
FEB-2014	40	4	7	10	4	13	316
MAR-2014	36	2	2	9	10	13	405
APR-2014	27	3	6	2	5	10	355
MAY-2014	38	2	4	3	10	18	500
JUN-2014	24	3	1	6	6	7	400
JUL-2014	34	3	7	7	5	13	350
AUG-2014	18	3	1	3	5	6	410
SEP-2014	25	5	3	3	4	9	395
OCT-2014	21	1	4	6	4	5	315
NOV-2014	19	5	1	0	4	8	475
DEC-2014	39	3	5	7	11	13	401
JAN-2015	24	2	2	8	3	9	370
FEB-2015	37	3	3	8	5	16	457
MAR-2015	30	2	5	5	8	8	393
APR-2015	27	7	2	4	3	11	420

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2014	10030	2580
FEB-2014	10053	2574
MAR-2014	10066	2560
APR-2014	10096	2563
MAY-2014	10120	2557
JUN-2014	10155	2567
JUL-2014	10167	2555
AUG-2014	10216	2589
SEP-2014	10258	2599
OCT-2014	10281	2608
NOV-2014	10312	2630
DEC-2014	10353	2634
JAN-2015	10395	2664
FEB-2015	10441	2670
MAR-2015	10480	2678
APR-2015	10505	2693

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved

**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
April 2015

N = 6856

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY









3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2015

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2015

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2015

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2015

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

April 2015

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	35-49	13	15	10
	50+	18	28	11
	<b>Total HSDA:</b>	<b>31</b>	<b>43</b>	<b>21</b>
KOOTENAY BOUNDARY	0-19	1	1	1
	20-34	3	3	1
	35-49	20	25	14
	50+	43	58	34
	<b>Total HSDA:</b>	<b>67</b>	<b>87</b>	<b>50</b>
OKANAGAN	0-19	3	3	2
	20-34	22	23	16
	35-49	92	108	68
	50+	178	260	139
	<b>Total HSDA:</b>	<b>295</b>	<b>394</b>	<b>225</b>
THOMPSON/CARIBOO/ SHUSWAP	0-19	6	6	1
	20-34	16	16	13
	35-49	57	73	46
	50+	88	125	73
	<b>Total HSDA:</b>	<b>167</b>	<b>220</b>	<b>133</b>
<b>Total HA:</b>		<b>560</b>	<b>744</b>	<b>429</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	10	10	4
	20-34	41	42	30
	35-49	182	221	138
	50+	327	471	257
<b>Total HA:</b>		<b>560</b>	<b>744</b>	<b>429</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	433	588	336
Female	127	156	93

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	429	52	540	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	16	9
	5 years or more	6	4
	<5 years	9	8
	<b>Total HSDA:</b>	<b>31</b>	<b>21</b>
KOOTENAY BOUNDARY	10 years or more	31	21
	5 years or more	17	14
	<5 years	19	15
	<b>Total HSDA:</b>	<b>67</b>	<b>50</b>
OKANAGAN	10 years or more	153	108
	5 years or more	76	61
	<5 years	66	56
	<b>Total HSDA:</b>	<b>295</b>	<b>225</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	83	57
	5 years or more	35	33
	<5 years	49	43
	<b>Total HSDA:</b>	<b>167</b>	<b>133</b>
<b>Total HA:</b>		<b>560</b>	<b>429</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	283	195
	5 years or more	134	112
	<5 years	143	122
<b>Total HA:</b>		<b>560</b>	<b>429</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	34	46	13	19
KOOTENAY BOUNDARY	58	106	25	40
OKANAGAN	185	631	69	222
THOMPSON/CARIBOO/SHUSWAP	121	402	43	106
<b>Total:</b>	<b>398</b>	<b>1185</b>	<b>150</b>	<b>387</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	1
KOOTENAY BOUNDARY	11
OKANAGAN	39
THOMPSON/CARIBOO/SHUSWAP	38
<b>Total:</b>	<b>89</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA







#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	5
	20-34	24	25	19
	35-49	126	139	94
	50+	147	204	117
	<b>Total HSDA:</b>	<b>304</b>	<b>375</b>	<b>235</b>
FRASER NORTH	0-19	20	20	4
	20-34	105	106	87
	35-49	358	412	268
	50+	439	679	360
	<b>Total HSDA:</b>	<b>922</b>	<b>1217</b>	<b>719</b>
FRASER SOUTH	0-19	13	13	5
	20-34	93	95	72
	35-49	362	410	295
	50+	382	571	320
	Unknown	0	1	0
	<b>Total HSDA:</b>	<b>850</b>	<b>1090</b>	<b>692</b>
<b>Total HA:</b>		<b>2076</b>	<b>2682</b>	<b>1646</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	40	40	14
	20-34	222	226	178
	35-49	846	961	657
	50+	968	1454	797
	Unknown	0	1	0
<b>Total HA:</b>		<b>2076</b>	<b>2682</b>	<b>1646</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1562	2052	1263
Female	514	630	383

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1646	49	600	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration  
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	134	99
	5 years or more	92	72
	<5 years	78	64
	<b>Total HSDA:</b>	<b>304</b>	<b>235</b>
FRASER NORTH	10 years or more	428	310
	5 years or more	235	182
	<5 years	259	227
	<b>Total HSDA:</b>	<b>922</b>	<b>719</b>
FRASER SOUTH	10 years or more	381	296
	5 years or more	225	188
	<5 years	244	208
	<b>Total HSDA:</b>	<b>850</b>	<b>692</b>
<b>Total HA:</b>		<b>2076</b>	<b>1646</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	943	705
	5 years or more	552	442
	<5 years	581	499
<b>Total HA:</b>		<b>2076</b>	<b>1646</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
FRASER Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	122	363	40	71
FRASER NORTH	224	1332	63	268
FRASER SOUTH	198	1143	44	356
<b>Total:</b>	<b>544</b>	<b>2838</b>	<b>147</b>	<b>695</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	178
FRASER NORTH	599
FRASER SOUTH	472
<b>Total:</b>	<b>1249</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	2	2	0
	20-34	21	21	20
	35-49	87	101	71
	50+	191	309	168
	<b>Total HSDA:</b>	<b>301</b>	<b>433</b>	<b>259</b>
RICHMOND	0-19	8	8	2
	20-34	18	18	15
	35-49	51	54	43
	50+	68	107	56
	<b>Total HSDA:</b>	<b>145</b>	<b>187</b>	<b>116</b>
VANCOUVER	0-19	58	61	8
	20-34	403	412	311
	35-49	1657	1947	1265
	50+	2270	3783	1819
	<b>Total HSDA:</b>	<b>4388</b>	<b>6203</b>	<b>3403</b>
<b>Total HA:</b>	<b>4834</b>	<b>6823</b>	<b>3778</b>	

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	68	71	10
	20-34	442	451	346
	35-49	1795	2102	1379
	50+	2529	4199	2043
<b>Total HA:</b>		<b>4834</b>	<b>6823</b>	<b>3778</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
	2	2	0
Male	4244	5993	3336
Female	588	828	442

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3778	50	590	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	169	139
	5 years or more	47	43
	<5 years	85	77
	<b>Total HSDA:</b>	<b>301</b>	<b>259</b>
RICHMOND	10 years or more	69	50
	5 years or more	31	24
	<5 years	45	42
	<b>Total HSDA:</b>	<b>145</b>	<b>116</b>
VANCOUVER	10 years or more	2155	1559
	5 years or more	1084	880
	<5 years	1149	964
	Never on ART	0	0
	<b>Total HSDA:</b>	<b>4388</b>	<b>3403</b>
<b>Total HA:</b>	<b>4834</b>	<b>3778</b>	

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	2393	1748
5 years or more	1162	947
<5 years	1279	1083
Never on ART	0	0
<b>Total HA:</b>	<b>4834</b>	<b>3778</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	137	354	52	84
RICHMOND	42	267	15	96
VANCOUVER	512	9529	201	5150
<b>Total:</b>	<b>691</b>	<b>10150</b>	<b>268</b>	<b>5330</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	5
RICHMOND	2
VANCOUVER	100
<b>Total:</b>	<b>107</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	2	2	0
	20-34	18	20	14
	35-49	82	96	72
	50+	150	242	123
	<b>Total HSDA:</b>		<b>252</b>	<b>360</b>
NORTH VANCOUVER ISLAND	0-19	2	2	1
	20-34	14	15	10
	35-49	37	42	33
	50+	54	81	43
	<b>Total HSDA:</b>		<b>107</b>	<b>140</b>
SOUTH VANCOUVER ISLAND	0-19	8	8	1
	20-34	43	45	29
	35-49	212	253	162
	50+	365	566	278
	<b>Total HSDA:</b>		<b>628</b>	<b>872</b>
<b>Total HA:</b>		<b>987</b>	<b>1372</b>	<b>766</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	12	12	2
	20-34	75	80	53
	35-49	331	391	267
	50+	569	889	444
<b>Total HA:</b>		<b>987</b>	<b>1372</b>	<b>766</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	797	1112	621
Female	190	260	145

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	766	51	450	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	114	92
	5 years or more	64	56
	<5 years	74	61
	<b>Total HSDA:</b>	<b>252</b>	<b>209</b>
NORTH VANCOUVER ISLAND	10 years or more	47	36
	5 years or more	23	21
	<5 years	37	30
	<b>Total HSDA:</b>	<b>107</b>	<b>87</b>
SOUTH VANCOUVER ISLAND	10 years or more	304	203
	5 years or more	153	122
	<5 years	171	145
	<b>Total HSDA:</b>	<b>628</b>	<b>470</b>
<b>Total HA:</b>		<b>987</b>	<b>766</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	465	331
	5 years or more	240	199
	<5 years	282	236
<b>Total HA:</b>		<b>987</b>	<b>766</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation







**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	166	511	83	160
NORTH VANCOUVER ISLAND	109	225	46	67
SOUTH VANCOUVER ISLAND	179	1474	48	506
<b>Total:</b>	<b>454</b>	<b>2210</b>	<b>177</b>	<b>733</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	43
NORTH VANCOUVER ISLAND	31
SOUTH VANCOUVER ISLAND	80
<b>Total:</b>	<b>154</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	1	1	0
	20-34	5	6	4
	35-49	18	20	11
	50+	14	19	9
	<b>Total HSDA:</b>	<b>38</b>	<b>46</b>	<b>24</b>
NORTH WEST	0-19	2	2	0
	20-34	8	12	6
	35-49	24	36	18
	50+	29	43	23
	<b>Total HSDA:</b>	<b>63</b>	<b>93</b>	<b>47</b>
NORTHERN INTERIOR	0-19	2	2	1
	20-34	31	34	25
	35-49	71	87	59
	50+	70	115	56
	<b>Total HSDA:</b>	<b>174</b>	<b>238</b>	<b>141</b>
<b>Total HA:</b>		<b>275</b>	<b>377</b>	<b>212</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	1
	20-34	44	52	35
	35-49	113	143	88
	50+	113	177	88
<b>Total HA:</b>		<b>275</b>	<b>377</b>	<b>212</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	171	238	133
Female	104	139	79

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	212	46	480	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	12	6
	5 years or more	10	6
	<5 years	16	12
	<b>Total HSDA:</b>	<b>38</b>	<b>24</b>
NORTH WEST	10 years or more	16	8
	5 years or more	22	19
	<5 years	25	20
	<b>Total HSDA:</b>	<b>63</b>	<b>47</b>
NORTHERN INTERIOR	10 years or more	45	28
	5 years or more	48	43
	<5 years	81	70
	<b>Total HSDA:</b>	<b>174</b>	<b>141</b>
<b>Total HA:</b>		<b>275</b>	<b>212</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	73	42
	5 years or more	80	68
	<5 years	122	102
<b>Total HA:</b>		<b>275</b>	<b>212</b>

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	28	54	5	8
NORTH WEST	60	139	19	28
NORTHERN INTERIOR	94	368	24	178
<b>Total:</b>	<b>182</b>	<b>561</b>	<b>48</b>	<b>214</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	17
NORTHERN INTERIOR	21
<b>Total:</b>	<b>44</b>

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender**

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	7	10	7
	KOOTENAY BOUNDARY	3	6	3
	OKANAGAN	15	28	7
	THOMPSON/CARIBOO/SHUSWAP	21	36	18
	<b>Total HA:</b>	<b>46</b>	<b>80</b>	<b>35</b>
FRASER	FRASER EAST	33	41	31
	FRASER NORTH	62	91	46
	FRASER SOUTH	70	96	58
	<b>Total HA:</b>	<b>165</b>	<b>228</b>	<b>135</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	23	42	20
	RICHMOND	9	14	8
	VANCOUVER	484	756	409
	<b>Total HA:</b>	<b>516</b>	<b>812</b>	<b>437</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	45	70	35
	NORTH VANCOUVER ISLAND	12	21	12
	SOUTH VANCOUVER ISLAND	33	68	27
	<b>Total HA:</b>	<b>90</b>	<b>159</b>	<b>74</b>
NORTHERN	NORTH EAST	9	11	6
	NORTH WEST	29	51	25
	NORTHERN INTERIOR	62	92	58
	<b>Total HA:</b>	<b>100</b>	<b>154</b>	<b>89</b>
<b>Total:</b>		<b>917</b>	<b>1433</b>	<b>770</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	585	926	490
Female	332	507	280

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	770	48	460	35

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** Persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a pill that contains EFAVIRENZ, TENOFOVIR and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Boosted PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Combination Therapy:** using at least two drugs simultaneously to more effectively combat a disease. Initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a pill that contains both ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

**Complera (CPL):** the Gilead and Janssen trade name for a pill that contains EMTRICITABINE, RILPIVIRINE and TENOFOVIR.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Delavirdine (Rescriptor, DLV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Agouron/ViiV Healthcare.





**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare that has demonstrated activity against HIV in treatment-experienced patients.

**Efavirenz (Sustiva, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences that has demonstrated activity against HIV in treatment-experienced patients.

**Emtricitabine (FTC):** a nucleoside analog from Gilead Sciences. It is currently available as a component of TRUVADA.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**Famciclovir (Famvir):** a PRODRUG for an acyclovir-like active compound. It is an approved therapy for shingles and recurrent outbreaks of herpes simplex-2.

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment program this current month.

**Indinavir (Crixivan, IDV):** a PROTEASE INHIBITOR from Merck.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** ViiV Healthcare's trade name for a pill that contains both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.





**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

**Maraviroc (MVC, Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** The net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug, such as AZT (ZIDOVUDINE), ddI (DIDANOSINE) or 3TC (LAMIVUDINE), whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds such as TENOFOVIR that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).







**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck that has activity against HIV in treatment-experienced patients.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure.

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a pill that contains ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR.

**Tenofovir (Viread, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Trizivir (TRZ):** ViiV Healthcare's trade name for a pill that combines ABACAVIR (ABC), ZIDOVUDINE (AZT) and LAMIVUDINE (3TC).

**Truvada (TRU):** the Gilead trade name for a pill that contains both TENOFOVIR and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

